ZyVersa’s Q3 Losses Soar to $19.8M as Cash Reserves Dwindle to $0.5M
ZyVersa Therapeutics has reported a sharp rise in financial losses for the third quarter of 2025. The company’s net losses jumped to $19.8 million, up $17.4 million from the same period last year. Despite raising $2.05 million in the quarter, its cash reserves now stand at just $0.5 million.
The company’s financial struggles deepened due to a $18.6 million impairment charge on research and development. This pushed pre-tax losses to $20.7 million, an increase of $18.3 million compared to 2024. General and administrative expenses fell slightly to $1.7 million, while research and development costs dropped to $0.4 million.
ZyVersa is developing therapies based on two proprietary technologies. The Cholesterol Efflux Mediator VAR 200 targets kidney diseases, with its lead indication being focal segmental glomerulosclerosis (FSGS). Potential future uses include Alport syndrome and diabetic kidney disease. Meanwhile, the Inflammasome ASC Inhibitor IC 100 focuses on cardiometabolic conditions, with possible expansion into rare kidney diseases.
With only $0.5 million in cash, the company can fund operations on a month-to-month basis. Management has warned that additional finance will be needed to cover liabilities and advance its pipeline. So far in 2025, ZyVersa has raised $4.05 million, but further cash is likely required within the next six months.
ZyVersa faces significant financial pressure after reporting a steep rise in losses for Q3 2025. The company’s limited cash reserves will only sustain operations short-term, forcing it to seek more finance soon. Its pipeline progress depends on securing additional cash in the coming months.
